Union-Cell Pharmaceutical

Union-Cell Pharmaceutical is a China-based biotechnology company focused on the development, manufacturing, and commercialization of recombinant protein therapeutics and monoclonal antibodies. The company is well-known for its portfolio of cytokine-based products, including recombinant human interleukin-11 (rhIL-11) and recombinant human granulocyte colony-stimulating factor (rhG-CSF), which are used to treat chemotherapy-induced cytopenias. Union-Cell operates large-scale GMP manufacturing facilities and maintains a robust R&D pipeline targeting oncology and immunology. By leveraging its expertise in protein engineering and cell culture, the company provides essential supportive care treatments for cancer patients across the Chinese market.